Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Editas Medicine, a CRISPR gene-editing company, will receive a $70 million payment from Celgene to develop T-cell therapies for cancer and autoimmune diseases. The deal updates a narrower collaboration that Editas struck with Juno Therapeutics in 2015 focused exclusively on cancer. Celgene acquired Juno, a CAR T-cell therapy company, in 2018. The new deal also allows Editas to work on natural killer cells.
This article has been sent to the following recipient: